Phase 1 Hematological Malignancy Clinical Trials
5 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Hematological Malignancy
M.D. Anderson Cancer Center64 enrolled1 locationNCT05110742
Recruiting
Phase 1Phase 2
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Hematological Malignancy (Leukemia- Lymphoma)
Grit Biotechnology46 enrolled1 locationNCT06948981
Recruiting
Phase 1
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Solid TumorHematological Malignancy
Onward Therapeutics150 enrolled4 locationsNCT05828459
Recruiting
Phase 1
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Multiple MyelomaB-cell LymphomaHematological Malignancy
The Third Affiliated Hospital of Southern Medical University60 enrolled1 locationNCT06758713
Recruiting
Phase 1
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
Advanced Solid TumorHematological Malignancy
Shanghai Yuyao Biotech Co., Ltd.96 enrolled1 locationNCT06225856